Goldman Sachs Group Inc Cullinan Oncology, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 702,138 shares of CGEM stock, worth $6.06 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
702,138
Previous 648,957
8.19%
Holding current value
$6.06 Million
Previous $4.91 Million
7.63%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding CGEM
# of Institutions
152Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$66 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.6 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$38 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$33.3 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.6 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $394M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...